ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q4 2024 Earnings Call Transcript

ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) Q4 2024 Earnings Call Transcript March 20, 2025

ARS Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $0.52, expectations were $-0.04.

Justin Chakma – Chief Business Officer:

Richard Lowenthal – Co-Founder, President and CEO:

Eric Karas – Chief Commercial Office:

Kathleen Scott – CFO:

Ryan Deschner – Raymond James:

Alexa Deemer – Cantor Fitzgerald:

Louise Chen – Scotia Bank:

Roanna Ruiz – Leerink Partners:

Lachlan Hanbury-Brown –...